我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

秋水仙碱在心血管疾病方面的研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第4期
页码:
483-487
栏目:
综述
出版日期:
2016-04-01

文章信息/Info

Title:
Advances in research of colchicine in cardiovascular diseases
作者:
姚国泰1; 黎 娟1; 陈 励2
（1.95948部队后勤部卫生队，甘肃 酒泉 732750；
2.第四军医大学航空航天生理学教研室，陕西 西安 710032）
Author(s):
YAO Guo-tai1;  LI Juan1;  CHEN Li2
(1.Medical Corps, Logistics Department, Unit 95948, Jiuquan 732750, Gansu, China；
2.Department of Aerospace Physiology, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
秋水仙碱; 心包炎; 冠状动脉疾病; 心房颤动; 心力衰竭
Keywords:
colchicine;  pericarditis;  coronary artery disease;  atrial fibrillation;  heart failure
分类号:
R54
DOI:
-
文献标识码:
A
摘要:
秋水仙碱为一种脂溶性有较长半衰期和较高生物利用率的生物碱，由于具有抗炎作用，最初被应用于治疗预防急性痛风和预防自身炎症性疾病的发作。它主要的作用机理是通过结合微管蛋白抑制微管的聚合，从而干扰白细胞及细胞因子的功能来发挥抗炎作用。随着人们对它的药理和毒理机制研究的不断深入，发现它特有的抗炎性在心包炎、冠脉疾病、房颤以及心衰等心血管疾病的防治中可发挥着重要的作用,现就将秋水仙碱在心血管系统的研究进展做一综述。
Abstract:
Colchicine, a lipid-soluble alkaloid with long terminal half-life and high bioavailability, is initially used to treat and prevent acute gout and to prevent autoinflammatory diseases due to its anti-inflammatory property. Its main mechanism of action is to inhibit microtubule polymerization by binding to tubulin, thus affecting the functions of leucocytes and cytokines. With better understanding of pharmacologic properties and toxicity of colchicine, colchicine is found to be beneficial in the prevention and treatment of cardiovascular diseases because of its unique anti-inflammatory property. Previous trials and studies have shown that colchicine plays a significant role in the treatment of cardiovascular diseases such as pericarditis, coronary artery disease, atrial fibrillation and heart failure. In this review, we briefly review the role of colchicine in the prevention and treatment of cardiovascular diseases.

参考文献/References

[1]Taylor EW.The Mechanism of Colchicine Inhibition of Mitosis.I.Kinetics of Inhibition and the Binding of H3-Colchicine[J].J Cell Biol,1965,25(Suppl):145-160.
[2]Terkeltaub RA.Colchicine update:2008.[J].Semin Arthritis Rheum,2009,38(6):411-419.
[3]Rudolph SA,Greengard P,Malawista SE.Effects of colchicine on cyclic AMP levels in human leukocytes.Proc[J].Natl.Acad.Sci.U.S.A,1977,74(8):3404-3408.
[4]Cronstein BN,Molad Y, Reibman J,et al.Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils[J].J Clin.Invest,1995,96(2):994-1002.
[5]Paschke S,Weidner AF,Paust T,et al.Technical advance:Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments[J].J Leukoc Biol,2013,94(5):1091-1096.
[6]Imazio M.Contemporary management of pericardial diseases[J].Curr Opin Cardiol,2012,27(3):308-317.
[7]Imazio M,Bobbio M,Cecchi E,et al.Colchicine in addition to conventional therapy for acute pericarditis:results of the Colchicine for acute Pericarditis(COPE)trial[J].Circulation,2005,112(13):2012-2016.
[8]Imazio M,Brucato A,Cemin R,et al.A randomized trial of colchicines for acute pericarditis[J].N Engl J Med,2013,369(16):1522-1528.
[9]Lilly LS.Treatment of acute and recurrent idiopathic pericarditis[J].Circulation,2013,127(16):1723-1726.
[10]Imazio M,Brucato A,Belli R,et al.Colchicine for the prevention of pericarditis:what we know and what we do not know in 2014-systematic review and meta-analysis[J].J Cardiovasc Med,2014,15(12):840-846.
[11]Imazio M,Trinchero R,Brucato A,et al.Colchicine for the prevention of the post-pericardiotomy SyndromeCOPPS):amulticentre,randomized,double-blind,placebo-controlled trial[J].Eur Heart J,2010,31(22):2749-2754.
[12]Imazio M,Brucato A,Ferrazzi P,et al.Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation:the COPPS-2 randomized clinicaltrial[J].J Am Med Assoc,2014,312(10): 1016-1023.
[13]Imazio M.Treatment of recurrent pericarditis[J].Rev Esp Cardiol,2014,67(5):345-348.
[14]Imazio M,Belli R,Brucato A,et al.“Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): A multicenter, double-blind, placebo-controlled, randomised trial”[J].Lancet,2014,383(9936):2232-2237.
[15]Olsen AM,Fosbol EL,Lindhardsen J,et al.Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients-a nationwide study[J].PLoS One,2013,8(1):e54309.
[16]Nidorf SM,Thompson PL.Effect of colchicine(0.5 mg twice daily)on high-sensitivity Creactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease[J].Am J Cardiol,2007,99(6):805-807.
[17]Nidorf SM,Eikelboom JW,Budgeon CA,et al.Low- dose colchicines for secondary prevention of cardiovascular disease[J].Jam Coll Cardiol,2013,61(4): 404-410.
[18]Nidorf SM,Eikelboom JW,Thompson PL.Colchicine for secondary prevention of cardiovascular disease[J].Curr Atheroscler Rep,2014,16(3):391.
[19]Langevitz P,Livneh A,Neumann L,et al.Prevalence of ischemic heart disease in patients with familial Mediterranean fever[J].Isr Med Assoc J,2000,3(1):9-12.
[20]Crittenden DB,Lehmann RA,Schneck L,et al.Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout[J].J Rheumatol,2012,39(7):1458-1464.
[21]Libby P,Schwartz D,Brogi E,et al.A cascade model for restenosis.A special case of atherosclerosis progression[J].Circulation,1992,86(6 Suppl):III47-III52.
[22]O'Keefe JH Jr,McCallister BD,Bateman TM,et al.Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty[J].J Am Coll Cardiol,1992,19(7):1597-1600.
[23]Deftereos S,Giannopoulos G,Raisakis K,et al.Colchicine treatment for prevention of bare-metal stent restenosis in diabetics[J].J Am Coll Cardiol,2013,61(16):1679-1685.
[24]Hoffmann R,Mintz GS.Coronary in-stent restenosisdpredictors,treatment and prevention[J].Eur Heart J,2000,21(21):1739-1749.
[25]Giannopoulos G,Angelidis C,Kouritas VK,et al.Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting[J].Am J Cardiol,2015,115(10):1376-1381.
[26]Yeh YT,Liu CW,Wu YW.The Benefit from Anti- Inflammatory Properties of Colchicine in Cardiovascular Diseases[J].Am J Cardiol,2015,116(3):493.
[27]Imazio M,Brucato A,Ferrazzi P,et al.Colchicine reduces postoperative atrial fibrillation: results of the colchicines for the prevention of the postpericardiotomy syndrome(COPPS)atrial fibrillation substudy[J].Circulation,2011,124(21):2290-2295
[28]Deftereos S,Giannopoulos G,Efremidis M,et al.Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein iso-lation:mid-term efficacy and effect on quality of life[J].Heart Rhythm,2014,11(4):620-628.
[29]Levine B,Kalman J,Fillit HM,et al.Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J].N Engl J Med,1990,323(4):236-241.
[30]Deftereos S,Giannopoulos G,Panagopoulou V,et al.Anti-inflammatory treatment with colchicines in stable chronic heart failure: a prospective,randomized study[J].J Am Coll HF,2014,2(2):131-137.

备注/Memo

备注/Memo:
收稿日期：2015-02-01.
通讯作者：陈励，助教，主要从事失重心血管效应及其防护 Email:764266457@qq.com
作者简介：姚国泰，住院医师 Email:564309095@qq.com
更新日期/Last Update: 2016-04-01